title: Bevacizumab and Temozolomide Plus Radiation Regimen for Glioblastoma Multiforme.
abstract: The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc., 4201 Wilson Blvd #110-545, Arlington, VA 22203, e-mail: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net.
authors.affiliation: Chief, Hematology-Oncology Pharmacy Service, Department of Pharmacy, Madigan Army Medical Center , Tacoma, Washington . The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or reflecting the views of the US Department of the Army or the Department of Defense.
authors.forename: Matthew R
authors.initials: MR
authors.lastname: Rutledge
authors.affiliation: Chief, Hematology-Oncology Pharmacy Service, Department of Pharmacy, Madigan Army Medical Center , Tacoma, Washington . The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or reflecting the views of the US Department of the Army or the Department of Defense.
authors.forename: J Aubrey
authors.initials: JA
authors.lastname: Waddell
authors.affiliation: Chief, Hematology-Oncology Pharmacy Service, Department of Pharmacy, Madigan Army Medical Center , Tacoma, Washington . The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or reflecting the views of the US Department of the Army or the Department of Defense.
authors.forename: Dominic A
authors.initials: DA
authors.lastname: Solimando
references.citation: J Neurosurg. 2012 Feb;116(2):341-5
references.pmid: 22035272
references.citation: Int J Pharm Compd. 2006 Sep-Oct;10(5):396-9
references.pmid: 23974320
references.citation: J Clin Oncol. 2006 Jul 1;24(19):3187-205
references.pmid: 16682719
references.citation: Ann Oncol. 2010 May;21 Suppl 5:v232-43
references.pmid: 20555089
references.citation: J Clin Oncol. 2011 Jan 10;29(2):142-8
references.pmid: 21135282
references.citation: J Neurooncol. 2015 Mar;122(1):135-43
references.pmid: 25524817
references.citation: Br J Cancer. 2001 Oct 19;85(8):1099-101
references.pmid: 11710819
references.citation: Support Care Cancer. 1994 May;2(3):177-83
references.pmid: 8032704
references.citation: N Engl J Med. 2014 Feb 20;370(8):699-708
references.pmid: 24552317
references.citation: Expert Rev Clin Pharmacol. 2011 Mar;4(2):233-42
references.pmid: 21666852
references.citation: Anticancer Drugs. 1998 Jun;9(5):381-5
references.pmid: 9660533
references.citation: Curr Oncol. 2014 Jun;21(3):e493-503
references.pmid: 24940109
references.citation: Curr Opin Neurol. 2010 Dec;23(6):597-602
references.pmid: 20962642
references.citation: J Clin Oncol. 2011 Nov 1;29(31):4189-98
references.pmid: 21947834
references.citation: Clin Cancer Res. 2014 Oct 1;20(19):5023-31
references.pmid: 25107913
references.citation: J Cancer Res Clin Oncol. 1993;119(6):350-4
references.pmid: 8383688
references.citation: N Engl J Med. 2014 Feb 20;370(8):709-22
references.pmid: 24552318